<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632526</url>
  </required_header>
  <id_info>
    <org_study_id>D7550C00001</org_study_id>
    <nct_id>NCT02632526</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single
      and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to
      assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy
      male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single
      and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to
      assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy
      male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2016</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B).</measure>
    <time_frame>From screening to last followup visit (7-10 days after last dose), up to 6 weeks (Part A) and up to 8 weeks (Part B)</time_frame>
    <description>To assess the safety and tolerability of AZD5718 following oral administration of SAD (Part A) and MAD (Part B).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess area under the concentration-time curve from time zero extrapolated to infinity and was estimated by AUC(0-last) + Clast/λz (Clast - the last observed quantifiable concentration) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1 of Part B</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-last)) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess area under the area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUC(0-last)) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC(0-τ)) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1, Day 9 and Day 10 of Part B</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess observed maximum plasma concentration (Cmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1, Day 9 and Day 10 (Part B only)</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the observed maximum plasma concentration (Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess the time to reach the observed maximum plasma concentration (tmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1, Day 9 and Day 10 (Part B only)</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the time to reach the observed maximum plasma concentration (tmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess Rate and extent of absorption of AZD5718 by assessment of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1 and Day 10 (Part B only)</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent total body clearance after extravascular administration estimated as dose divided by AUC (CL/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1 and Day 10 of Part B</time_frame>
    <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of CL/F estimated as dose divided by AUC (for Day 1 only) and dose divided by AUCτ on Day 10 following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)</time_frame>
    <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of AUC for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)</time_frame>
    <description>To assess the relative bioavailability by AUC between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of Cmax for Part A - Amorphous and Crystalline Suspension</measure>
    <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
    <description>To assess the relative bioavailability by Cmax between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for AUC(0-τ) (RAC AUC(0-τ)) for Part B - Amorphous Suspension</measure>
    <time_frame>Day 1 and Day 9 (Part B only)</time_frame>
    <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B) Accumulation ratio calculated as AUC0-τ Day 10/AUC0-τ Day 1 (first dose) for Part B under fasted condition and presented values for Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for Cmax (RAC Cmax) for Part B (Amorphous Suspension) Under Fasted Condition</measure>
    <time_frame>Day 1 and Day 9 (Part B only)</time_frame>
    <description>To assess the rate and extent of absorption of AZD5718 by evaluation of accumulation ratio for Cmax (RAC Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B). Accumulation ratio calculated as Cmax Day 10/Cmax Day 1 (first dose) for Part B under fasted condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Temporal Change Parameter in Systemic Exposure (TCP) for Part B (Amorphous Suspension) Under Fasted Condition</measure>
    <time_frame>At Day 10 (Part B only)</time_frame>
    <description>To assess rate and extent of absorption of AZD5718 by assessment of the temporal change parameter in systemic exposure (TCP) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B).
TCP calculated as AUCτDay10/AUCDay 1 and presented values for Day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</measure>
    <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
    <description>The effect of food was evaluated by the assessment of the PK parameter (Cmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</measure>
    <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
    <description>The effect of food was evaluated by the assessment of the PK parameter (AUC(0-t) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</measure>
    <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
    <description>The effect of food was evaluated by the assessment of the PK parameter(tmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted at the Last Sampling Interval (CumAe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</measure>
    <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
    <description>To assess urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</measure>
    <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
    <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</measure>
    <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
    <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</measure>
    <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
    <description>To assess the urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</measure>
    <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
    <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</measure>
    <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
    <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Analysis by ex Vivo Stimulation of Leukotriene B4 (LTB4) Production Using Calcium Ionophore for Part A -Amorphous and Crystalline Suspension</measure>
    <time_frame>Admission to 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose (Part A only)</time_frame>
    <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Analysis by ex Vivo Stimulation of LTB4 Production Using Calcium Ionophore for Part B - Amorphous Suspension</measure>
    <time_frame>Admission, predose and 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose</time_frame>
    <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following multiple administration of AZD5718 Amorphous suspension (Part B only)</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy Male Subjects</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose 25 mg/day, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 5 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 6 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718, crystalline form, treatment 7 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 crystalline form, treatment 8 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 1 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 2 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous/crystalline, repeat 3 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, repeat 1 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5718 amorphous form, repeat 2 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)</intervention_name>
    <description>Oral suspension single dose</description>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 1 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 2 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline, repeat 3 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 crystalline form, treatment 8 (Part A)</arm_group_label>
    <arm_group_label>AZD5718, crystalline form, treatment 7 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)</intervention_name>
    <description>Single and multiple doses</description>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 5 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 6 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 1 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 2 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline, repeat 3 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718 placebo oral suspension</intervention_name>
    <description>Single and multiple doses</description>
    <arm_group_label>AZD5718 amorphous form, repeat 1 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, repeat 2 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 5 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 6 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 1 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 amorphous/crystalline form, repeat 2 (Part A)</arm_group_label>
    <arm_group_label>AZD5718 crystalline form, treatment 8 (Part A)</arm_group_label>
    <arm_group_label>AZD5718, crystalline form, treatment 7 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)</intervention_name>
    <description>Single and multiple doses</description>
    <arm_group_label>AZD5718 amorphous form, repeat 1 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, repeat 2 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 1 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 2 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 3 (Part B)</arm_group_label>
    <arm_group_label>AZD5718 amorphous form, treatment 4 (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures

          2. Healthy male subjects aged 18 - 50 years, inclusive, with suitable veins for
             cannulation or repeated venepuncture

          3. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg inclusive

          4. Provision of signed, written and dated informed consent for optional genetic research

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study

          2. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 4
             weeks of the administration of investigational medicinal product (IMP)

          4. Any clinically significant abnormalities in clinical chemistry, haematology, or
             urinalysis results at screening and check-in, as judged by the investigator,
             including:

               -  Alanine aminotransferase (ALT) &gt; upper limit of normal (ULN);

               -  Aspartate aminotransferase (AST) &gt; ULN;

               -  Bilirubin (total) &gt; ULN; and

               -  Gamma glutamyl transpeptidase (GGT) &gt; ULN

          5. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV)

          6. Suspicion or known Gilbert's syndrome

          7. Abnormal vital signs, after 10 minutes supine rest, at screening and check-in, defined
             as any of the following:

               -  Systolic blood pressure(BP) (SBP) &lt; 90mmHg or ≥ 140 mmHg;

               -  Diastolic BP (DBP) &lt; 50mmHg or ≥ 90 mmHg; and

               -  Pulse &lt; 45 or &gt; 85 beats per minute (bpm)

          8. Any clinically significant abnormalities (at screening and check-in) in rhythm,
             conduction or morphology of the resting ECG and any clinically significant
             abnormalities in the 12-lead ECG, as considered by the investigator that may interfere
             with the interpretation of QTc interval changes, including abnormal ST-T-wave
             morphology, particularly in the protocol defined primary lead or left ventricular
             hypertrophy

          9. Prolonged QTcF (QT interval corrected for heart rate using Fridericia's formula) &gt; 450
             ms or shortened QTcF &lt; 340 ms or family history of long QT syndrome, at screening and
             check-in

         10. PR(PQ) interval (ECG interval measured from the onset of the P wave to the onset of
             the QRS complex) shortening &lt; 120 ms (PR &gt; 110 ms but &lt; 120 ms is acceptable if there
             is no evidence of ventricular pre-excitation), at screening and check-in

         11. PR (PQ) interval prolongation (&gt; 240 ms) intermittent second (Wenckebach block while
             asleep is not exclusive) or third degree AV block, or AV dissociation, at screening
             and check-in

         12. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle
             branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS &gt; 110 ms.
             Subjects with QRS &gt; 110 ms but &lt; 115 ms are acceptable if there is no evidence of, for
             example, ventricular hypertrophy or pre-excitation, at screening and check-in

         13. Known or suspected history of drug abuse, as judged by the investigator

         14. Current smokers or those who have smoked or used nicotine products within the 3 months
             prior to screening

         15. Any history of alcohol abuse or excessive intake of alcohol, as judged by the
             investigator

         16. Positive screen for drugs of abuse, alcohol or cotinine (nicotine) at screening or
             admission to the unit

         17. History of severe allergy/hypersensitivity or ongoing clinically significant
             allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity
             to drugs with a similar chemical structure or class to AZD5718

         18. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate),
             as judged by the investigator

         19. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks
             prior to the first administration of IMP

         20. Use of any prescribed or non-prescribed medication including antacids, analgesics
             (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of
             20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to
             the administration of IMP or longer if the medication has a long half-life

         21. Plasma donation within 1 month of screening or any blood donation/blood loss &gt; 500 mL
             during the 3 months prior to screening

         22. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 3 months of the administration of IMP in this study.
             The period of exclusion is 3 months after the final dose from a previous study

         23. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship,
             trusteeship, or committed to an institution by governmental or juridical order

         24. Involvement of any AstraZeneca, PAREXEL or study site employee or their close
             relatives

         25. Judgment by the investigator that the subject should not participate in the study if
             they have any ongoing or recent (i.e., during the screening period) minor medical
             complaints that may interfere with the interpretation of study data or are considered
             unlikely to comply with study procedures, restrictions and requirements

         26. Subjects who are vegans or have medical dietary restrictions

         27. Subjects who cannot communicate reliably with the investigator

             In addition, any of the following is regarded as a criterion for exclusion from the
             genetic research:

         28. Previous bone marrow transplant

         29. Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
             genetic sample collection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, MBChB, FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2019</results_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD5718 oral suspension crystalline</keyword>
  <keyword>AZD5718 oral suspension amorphous</keyword>
  <keyword>Single ascending dose/multiple ascending dose (SAD/MAD)</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted on 96 healthy male participants at a single center: PAREXEL Early Phase Clinical Unit - London. This study consisted of 2 parts: Part A - single ascending dose (SAD) and Part B - multiple ascending dose (MAD).</recruitment_details>
      <pre_assignment_details>Screening period was from Day -28 and Day -1. Participants signed informed consent form; demographic data, medical history and concomitant medication details were collected; weight, height and body mass index were measured; inclusion/exclusion criteria were checked, serology and screening of urinary drugs of abuse, alcohol and cotinine were done</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 in amorphous state at dose levels 25 mg, 50 mg, 100 mg, 300 mg, 600 mg &amp; 1200mg with 6 participants in each dose level</description>
        </group>
        <group group_id="P2">
          <title>Part A (Crystalline Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 in crystalline state at dose levels 100 mg &amp; 300 mg with 6 participants in each dose level</description>
        </group>
        <group group_id="P3">
          <title>Part B (Amorphous Suspension)</title>
          <description>Participants received multiple daily doses of oral suspension of AZD5718 in amorphous state at dose levels 60 mg, 180 mg, 360 mg &amp; 600 mg with 6 participants in each dose level</description>
        </group>
        <group group_id="P4">
          <title>Placebo - Part A (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Amorphous suspension)</description>
        </group>
        <group group_id="P5">
          <title>Placebo - Part A (Crystalline Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Crystalline suspension)</description>
        </group>
        <group group_id="P6">
          <title>Placebo - Part B (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part B (Amorphous suspension)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 in amorphous state at dose levels 25 mg, 50 mg, 100 mg, 300 mg, 600 mg &amp; 1200mg with 6 participants in each dose level</description>
        </group>
        <group group_id="B2">
          <title>Part A (Crystalline Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 in crystalline state at dose levels 100 mg &amp; 300 mg with 6 participants in each dose level</description>
        </group>
        <group group_id="B3">
          <title>Part B (Amorphous Suspension)</title>
          <description>Participants received multiple daily doses of oral suspension of AZD5718 in amorphous state at dose levels 60 mg, 180 mg, 360 mg &amp; 600 mg with 6 participants in each dose level</description>
        </group>
        <group group_id="B4">
          <title>Placebo - Part A (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Amorphous suspension)</description>
        </group>
        <group group_id="B5">
          <title>Placebo - Part A (Crystalline Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Crystalline suspension)</description>
        </group>
        <group group_id="B6">
          <title>Placebo - Part B (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part B (Amorphous suspension)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The number analyzed in row differs from overall since the data for Part A (Amorphous Suspension), Part A (Crystalline Suspension), Part B (Amorphous Suspension), Placebo - Part A (Amorphous Suspension), Placebo - Part A (Crystalline Suspension), Placebo - Part B (Amorphous Suspension) are presented in different rows.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="8.85"/>
                    <measurement group_id="B7" value="34.3" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="33.2" spread="11.64"/>
                    <measurement group_id="B7" value="33.2" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="35.5" spread="7.32"/>
                    <measurement group_id="B7" value="35.5" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="34.9" spread="10.23"/>
                    <measurement group_id="B7" value="34.9" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="33.3" spread="5.62"/>
                    <measurement group_id="B7" value="33.3" spread="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="38.3" spread="5.31"/>
                    <measurement group_id="B7" value="38.3" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other: Mixed: Black And White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="96"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>The number analyzed in row differs from overall since the data for Part A (Amorphous Suspension), Part A (Crystalline Suspension), Part B (Amorphous Suspension), Placebo - Part A (Amorphous Suspension), Placebo - Part A (Crystalline Suspension), Placebo - Part B (Amorphous Suspension) are presented in different rows.</population>
          <units>Centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179.0" spread="6.32"/>
                    <measurement group_id="B7" value="179.0" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="180.9" spread="6.95"/>
                    <measurement group_id="B7" value="180.9" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="178.0" spread="7.07"/>
                    <measurement group_id="B7" value="178.0" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="176.3" spread="5.33"/>
                    <measurement group_id="B7" value="176.3" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="174.3" spread="3.30"/>
                    <measurement group_id="B7" value="174.3" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="175.5" spread="7.37"/>
                    <measurement group_id="B7" value="175.5" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>The number analyzed in row differs from overall since the data for Part A (Amorphous Suspension), Part A (Crystalline Suspension), Part B (Amorphous Suspension), Placebo - Part A (Amorphous Suspension), Placebo - Part A (Crystalline Suspension), Placebo - Part B (Amorphous Suspension) are presented in different rows.</population>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.24" spread="10.982"/>
                    <measurement group_id="B7" value="79.24" spread="10.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="74.89" spread="5.450"/>
                    <measurement group_id="B7" value="74.89" spread="5.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="77.95" spread="10.369"/>
                    <measurement group_id="B7" value="77.95" spread="10.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="76.70" spread="9.547"/>
                    <measurement group_id="B7" value="76.70" spread="9.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="80.50" spread="2.647"/>
                    <measurement group_id="B7" value="80.50" spread="2.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="74.34" spread="5.532"/>
                    <measurement group_id="B7" value="74.34" spread="5.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <population>The number analyzed in row differs from overall since the data for Part A (Amorphous Suspension), Part A (Crystalline Suspension), Part B (Amorphous Suspension), Placebo - Part A (Amorphous Suspension), Placebo - Part A (Crystalline Suspension), Placebo - Part B (Amorphous Suspension) are presented in different rows.</population>
          <units>Kilogram/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.71" spread="3.014"/>
                    <measurement group_id="B7" value="24.71" spread="3.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="22.94" spread="2.265"/>
                    <measurement group_id="B7" value="22.94" spread="2.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="24"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="24.56" spread="2.456"/>
                    <measurement group_id="B7" value="24.56" spread="2.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="24.68" spread="2.764"/>
                    <measurement group_id="B7" value="24.68" spread="2.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part A (Crystalline Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="4"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="26.55" spread="1.634"/>
                    <measurement group_id="B7" value="26.55" spread="1.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo - Part B (Amorphous Suspension)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="8"/>
                    <count group_id="B7" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="24.14" spread="1.133"/>
                    <measurement group_id="B7" value="24.14" spread="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B).</title>
        <description>To assess the safety and tolerability of AZD5718 following oral administration of SAD (Part A) and MAD (Part B).</description>
        <time_frame>From screening to last followup visit (7-10 days after last dose), up to 6 weeks (Part A) and up to 8 weeks (Part B)</time_frame>
        <population>All randomized subjects who received at least 1 dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 in amorphous state at dose levels 25 mg, 50 mg, 100 mg, 300 mg, 600 mg &amp; 1200mg with 6 participants in each dose level</description>
          </group>
          <group group_id="O2">
            <title>Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 in crystalline state at dose levels 100 mg &amp; 300 mg with 6 participants in each dose level</description>
          </group>
          <group group_id="O3">
            <title>Part B (Amorphous Suspension)</title>
            <description>Participants received multiple daily doses of oral suspension of AZD5718 in amorphous state at dose levels 60 mg, 180 mg, 360 mg &amp; 600 mg with 6 participants in each dose level</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Part A (Amorphous Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part A (Amorphous suspension)</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Part A (Crystalline Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part A (Crystalline suspension)</description>
          </group>
          <group group_id="O6">
            <title>Placebo - Part B (Amorphous Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part B (Amorphous suspension)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B).</title>
          <description>To assess the safety and tolerability of AZD5718 following oral administration of SAD (Part A) and MAD (Part B).</description>
          <population>All randomized subjects who received at least 1 dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE with outcome = death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (including events with outcome = death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation of IMP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess area under the concentration-time curve from time zero extrapolated to infinity and was estimated by AUC(0-last) + Clast/λz (Clast - the last observed quantifiable concentration) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess area under the concentration-time curve from time zero extrapolated to infinity and was estimated by AUC(0-last) + Clast/λz (Clast - the last observed quantifiable concentration) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376.3" spread="38.09"/>
                    <measurement group_id="O2" value="727.0" spread="15.39"/>
                    <measurement group_id="O3" value="1441" spread="45.26"/>
                    <measurement group_id="O4" value="8462" spread="20.05"/>
                    <measurement group_id="O5" value="18810" spread="42.09"/>
                    <measurement group_id="O6" value="35840" spread="33.71"/>
                    <measurement group_id="O7" value="706.7" spread="24.24"/>
                    <measurement group_id="O8" value="1006" spread="43.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0433</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.322</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.182</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0124</ci_lower_limit>
            <ci_upper_limit>0.656</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part B - Amorphous Suspension</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1 of Part B</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) for Part B - Amorphous Suspension</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under plasma concentration-time curve from time zero extrapolated to infinity (AUC) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087" spread="24.01"/>
                    <measurement group_id="O2" value="3834" spread="40.94"/>
                    <measurement group_id="O3" value="10720" spread="28.80"/>
                    <measurement group_id="O4" value="17010" spread="47.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0813</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-last)) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess area under the area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUC(0-last)) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-last)) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess area under the area under the plasma concentration-curve from time zero to the time of last quantifiable concentration (AUC(0-last)) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.5" spread="87.15"/>
                    <measurement group_id="O2" value="701.5" spread="15.83"/>
                    <measurement group_id="O3" value="1408" spread="47.23"/>
                    <measurement group_id="O4" value="8395" spread="20.61"/>
                    <measurement group_id="O5" value="18740" spread="42.13"/>
                    <measurement group_id="O6" value="35760" spread="33.81"/>
                    <measurement group_id="O7" value="642.9" spread="21.55"/>
                    <measurement group_id="O8" value="933.2" spread="41.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC(0-τ)) for Part B - Amorphous Suspension</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1, Day 9 and Day 10 of Part B</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Area Under the Plasma Concentration-curve Over the Dosing Interval (AUC(0-τ)) for Part B - Amorphous Suspension</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1018" spread="22.40"/>
                    <measurement group_id="O2" value="3732" spread="41.19"/>
                    <measurement group_id="O3" value="10350" spread="28.84"/>
                    <measurement group_id="O4" value="16290" spread="48.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1441" spread="24.92"/>
                    <measurement group_id="O2" value="3312" spread="33.26"/>
                    <measurement group_id="O3" value="13790" spread="20.56"/>
                    <measurement group_id="O4" value="24890" spread="44.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1386" spread="27.40"/>
                    <measurement group_id="O2" value="5128" spread="46.90"/>
                    <measurement group_id="O3" value="12760" spread="31.00"/>
                    <measurement group_id="O4" value="23170" spread="47.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0851</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess observed maximum plasma concentration (Cmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess observed maximum plasma concentration (Cmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.14" spread="75.96"/>
                    <measurement group_id="O2" value="81.62" spread="36.39"/>
                    <measurement group_id="O3" value="170.3" spread="54.86"/>
                    <measurement group_id="O4" value="2358" spread="32.89"/>
                    <measurement group_id="O5" value="5052" spread="45.82"/>
                    <measurement group_id="O6" value="6875" spread="34.94"/>
                    <measurement group_id="O7" value="54.62" spread="28.35"/>
                    <measurement group_id="O8" value="80.24" spread="39.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0692</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.350</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.176</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0315</ci_lower_limit>
            <ci_upper_limit>0.669</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part B - Amorphous Suspension</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the observed maximum plasma concentration (Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1, Day 9 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part B - Amorphous Suspension</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the observed maximum plasma concentration (Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.3" spread="19.81"/>
                    <measurement group_id="O2" value="846.9" spread="48.00"/>
                    <measurement group_id="O3" value="2561" spread="31.72"/>
                    <measurement group_id="O4" value="4933" spread="47.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.4" spread="31.70"/>
                    <measurement group_id="O2" value="349.8" spread="34.99"/>
                    <measurement group_id="O3" value="3372" spread="22.69"/>
                    <measurement group_id="O4" value="5297" spread="43.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.8" spread="31.93"/>
                    <measurement group_id="O2" value="1243" spread="55.23"/>
                    <measurement group_id="O3" value="3209" spread="40.01"/>
                    <measurement group_id="O4" value="5693" spread="59.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0839</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.104</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess the time to reach the observed maximum plasma concentration (tmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess the time to reach the observed maximum plasma concentration (tmax) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="75.96" lower_limit="1.00" upper_limit="5.98"/>
                    <measurement group_id="O2" value="1.02" spread="36.39" lower_limit="1.00" upper_limit="2.98"/>
                    <measurement group_id="O3" value="1.00" spread="54.86" lower_limit="0.50" upper_limit="3.03"/>
                    <measurement group_id="O4" value="1.00" spread="32.89" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.00" spread="45.82" lower_limit="0.98" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.51" spread="34.94" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O7" value="3.00" spread="28.35" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="1.98" spread="39.73" lower_limit="1.00" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part B - Amorphous Suspension</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the time to reach the observed maximum plasma concentration (tmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1, Day 9 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Time to Reach the Observed Maximum Plasma Concentration (Tmax) for Part B - Amorphous Suspension</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the time to reach the observed maximum plasma concentration (tmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.01" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.98" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="3.51" lower_limit="2.00" upper_limit="6.02"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.50" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.98" upper_limit="1.02"/>
                    <measurement group_id="O3" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.49" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess Rate and extent of absorption of AZD5718 by assessment of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess Rate and extent of absorption of AZD5718 by assessment of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.90" spread="5.063" lower_limit="1.00" upper_limit="5.98"/>
                    <measurement group_id="O2" value="13.14" spread="4.684" lower_limit="1.00" upper_limit="2.98"/>
                    <measurement group_id="O3" value="13.30" spread="4.357" lower_limit="0.50" upper_limit="3.03"/>
                    <measurement group_id="O4" value="14.62" spread="5.361" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O5" value="11.62" spread="2.198" lower_limit="0.98" upper_limit="2.00"/>
                    <measurement group_id="O6" value="10.41" spread="1.851" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O7" value="19.97" spread="6.763" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="14.18" spread="2.653" lower_limit="1.00" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part B - Amorphous Suspension</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Half-life Associated With Terminal Slope of a Semi-logarithmic Plasma Concentration-time Curve (t½λz) for Part B - Amorphous Suspension</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 -From sampling time to 24 hrs; not true t½λz</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.450" spread="0.8084"/>
                    <measurement group_id="O2" value="5.489" spread="1.168"/>
                    <measurement group_id="O3" value="5.920" spread="0.5085"/>
                    <measurement group_id="O4" value="6.799" spread="2.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.65" spread="0.7718"/>
                    <measurement group_id="O2" value="11.29" spread="1.432"/>
                    <measurement group_id="O3" value="9.156" spread="1.014"/>
                    <measurement group_id="O4" value="10.23" spread="3.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent total body clearance after extravascular administration estimated as dose divided by AUC (CL/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent total body clearance after extravascular administration estimated as dose divided by AUC (CL/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Liters/Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.3" spread="60.18" lower_limit="1.00" upper_limit="5.98"/>
                    <measurement group_id="O2" value="155.5" spread="22.31" lower_limit="1.00" upper_limit="2.98"/>
                    <measurement group_id="O3" value="168.1" spread="74.10" lower_limit="0.50" upper_limit="3.03"/>
                    <measurement group_id="O4" value="80.84" spread="18.41" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O5" value="76.30" spread="29.08" lower_limit="0.98" upper_limit="2.00"/>
                    <measurement group_id="O6" value="78.88" spread="31.04" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O7" value="324.5" spread="77.99" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="714.6" spread="292.2" lower_limit="1.00" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part B - Amorphous Suspension</title>
        <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of CL/F estimated as dose divided by AUC (for Day 1 only) and dose divided by AUCτ on Day 10 following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
        <time_frame>Day 1 and Day 10 of Part B</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Total Body Clearance After Extravascular Administration Estimated as Dose Divided by AUC (CL/F) for Part B - Amorphous Suspension</title>
          <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of CL/F estimated as dose divided by AUC (for Day 1 only) and dose divided by AUCτ on Day 10 following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Liter/Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.6" spread="31.39"/>
                    <measurement group_id="O2" value="112.2" spread="45.10"/>
                    <measurement group_id="O3" value="77.96" spread="24.80"/>
                    <measurement group_id="O4" value="85.85" spread="36.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.85" spread="26.40"/>
                    <measurement group_id="O2" value="85.06" spread="35.38"/>
                    <measurement group_id="O3" value="65.65" spread="20.14"/>
                    <measurement group_id="O4" value="63.07" spread="28.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess rate and extent of absorption of AZD5718 by assessment of the apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2608" spread="447.6" lower_limit="1.00" upper_limit="5.98"/>
                    <measurement group_id="O2" value="2940" spread="1063" lower_limit="1.00" upper_limit="2.98"/>
                    <measurement group_id="O3" value="3490" spread="2433" lower_limit="0.50" upper_limit="3.03"/>
                    <measurement group_id="O4" value="1770" spread="992.9" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1264" spread="446.6" lower_limit="0.98" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1189" spread="538.9" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O7" value="8801" spread="2072" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O8" value="14630" spread="5751" lower_limit="1.00" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of AUC for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess the relative bioavailability by AUC between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8,12, 24, 36, and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg - AZD5718</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous/crystalline state</description>
          </group>
          <group group_id="O2">
            <title>300 mg - AZD5718</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous/crystalline state</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of AUC for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess the relative bioavailability by AUC between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="2433" lower_limit="34.0" upper_limit="70.7"/>
                    <measurement group_id="O2" value="11.9" spread="992.9" lower_limit="8.38" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of Cmax for Part A - Amorphous and Crystalline Suspension</title>
        <description>To assess the relative bioavailability by Cmax between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
        <time_frame>At post-dose (Days 1 to 3); 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose and folow up (Day 4 - 72 hours post-dose) (Part A only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg AZD5718</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous/crystalline state</description>
          </group>
          <group group_id="O2">
            <title>300 mg - AZD5718</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous/crystalline state</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Relative Bioavailability Between the Amorphous and Crystalline Form of AZD5718 (Part A) by Assessment of Cmax for Part A - Amorphous and Crystalline Suspension</title>
          <description>To assess the relative bioavailability by Cmax between the cohort receiving the crystalline suspension and the corresponding data from the cohort receiving the same dose of the amorphous suspension (Part A only). Crystalline suspension was compared to the reference amorphous suspension.
Note: Geometric mean ratios for crystalline/amorphous suspensions were calculated</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="2433" lower_limit="20.8" upper_limit="49.4"/>
                    <measurement group_id="O2" value="3.40" spread="992.9" lower_limit="2.35" upper_limit="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for AUC(0-τ) (RAC AUC(0-τ)) for Part B - Amorphous Suspension</title>
        <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B) Accumulation ratio calculated as AUC0-τ Day 10/AUC0-τ Day 1 (first dose) for Part B under fasted condition and presented values for Day 10</description>
        <time_frame>Day 1 and Day 9 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for AUC(0-τ) (RAC AUC(0-τ)) for Part B - Amorphous Suspension</title>
          <description>To assess rate and extent of absorption of AZD5718 by assessment of the Rate and extent of absorption of AZD5718 by assessment of accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B) Accumulation ratio calculated as AUC0-τ Day 10/AUC0-τ Day 1 (first dose) for Part B under fasted condition and presented values for Day 10</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.368" lower_limit="1.13" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.387" lower_limit="1.02" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.253" lower_limit="0.848" upper_limit="1.48"/>
                    <measurement group_id="O4" value="1.444" lower_limit="1.19" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for Cmax (RAC Cmax) for Part B (Amorphous Suspension) Under Fasted Condition</title>
        <description>To assess the rate and extent of absorption of AZD5718 by evaluation of accumulation ratio for Cmax (RAC Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B). Accumulation ratio calculated as Cmax Day 10/Cmax Day 1 (first dose) for Part B under fasted condition.</description>
        <time_frame>Day 1 and Day 9 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Accumulation Ratio for Cmax (RAC Cmax) for Part B (Amorphous Suspension) Under Fasted Condition</title>
          <description>To assess the rate and extent of absorption of AZD5718 by evaluation of accumulation ratio for Cmax (RAC Cmax) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B). Accumulation ratio calculated as Cmax Day 10/Cmax Day 1 (first dose) for Part B under fasted condition.</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Ratio, no units</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.368" lower_limit="1.13" upper_limit="1.57"/>
                    <measurement group_id="O2" value="1.387" lower_limit="1.02" upper_limit="1.56"/>
                    <measurement group_id="O3" value="1.253" lower_limit="0.848" upper_limit="1.48"/>
                    <measurement group_id="O4" value="1.444" lower_limit="1.19" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Temporal Change Parameter in Systemic Exposure (TCP) for Part B (Amorphous Suspension) Under Fasted Condition</title>
        <description>To assess rate and extent of absorption of AZD5718 by assessment of the temporal change parameter in systemic exposure (TCP) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B).
TCP calculated as AUCτDay10/AUCDay 1 and presented values for Day 10</description>
        <time_frame>At Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Temporal Change Parameter in Systemic Exposure (TCP) for Part B (Amorphous Suspension) Under Fasted Condition</title>
          <description>To assess rate and extent of absorption of AZD5718 by assessment of the temporal change parameter in systemic exposure (TCP) following a single AZD5718 dose on Day 1 and multiple daily dosing on Days 9 or 10 under fasted conditions (Part B).
TCP calculated as AUCτDay10/AUCDay 1 and presented values for Day 10</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Ratio, no units</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.280" lower_limit="1.08" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.349" lower_limit="1.01" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.211" lower_limit="0.822" upper_limit="1.44"/>
                    <measurement group_id="O4" value="1.385" lower_limit="1.12" upper_limit="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
        <description>The effect of food was evaluated by the assessment of the PK parameter (Cmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
        <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>180mg-Part B (Amorphous Suspension) -Fed State (Day 9)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
          <group group_id="O2">
            <title>180mg -Part B (Amorphous Suspension) -Fasted State (Day 10)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
          <description>The effect of food was evaluated by the assessment of the PK parameter (Cmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.8" spread="34.99"/>
                    <measurement group_id="O2" value="1243" spread="55.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cmax</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>28.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.98</ci_lower_limit>
            <ci_upper_limit>37.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
        <description>The effect of food was evaluated by the assessment of the PK parameter (AUC(0-t) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
        <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>180mg-Part B (Amorphous Suspension) -Fed State (Day 9)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
          <group group_id="O2">
            <title>180mg -Part B (Amorphous Suspension) -Fasted State (Day 10)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
          <description>The effect of food was evaluated by the assessment of the PK parameter (AUC(0-t) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3312" spread="33.26"/>
                    <measurement group_id="O2" value="5128" spread="46.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AUC(0-τ)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio</param_type>
            <param_value>64.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.34</ci_lower_limit>
            <ci_upper_limit>76.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
        <description>The effect of food was evaluated by the assessment of the PK parameter(tmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
        <time_frame>At Day 9 and Day 10 (Part B only)</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>180mg-Part B (Amorphous Suspension) -Fed State (Day 9)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
          <group group_id="O2">
            <title>180mg -Part B (Amorphous Suspension) -Fasted State (Day 10)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts under fed condition</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of the Effect of Food Following Administration of 180 mg AZD5718 With Food (Part B Day 9) and Fasted (Part B Day 10)</title>
          <description>The effect of food was evaluated by the assessment of the PK parameter(tmax) following multiple daily doses of 180 mg AZD5718 under fasted condition (Part B Day 10) and immediately following a high-fat breakfast (Part B Day 9)</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" lower_limit="2.00" upper_limit="6.02"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.98" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted at the Last Sampling Interval (CumAe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
        <description>To assess urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part A</description>
        <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted at the Last Sampling Interval (CumAe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
          <description>To assess urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part A</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.9" spread="125.0"/>
                    <measurement group_id="O2" value="439.8" spread="85.95"/>
                    <measurement group_id="O3" value="1030" spread="449.7"/>
                    <measurement group_id="O4" value="5960" spread="2027"/>
                    <measurement group_id="O5" value="13610" spread="3850"/>
                    <measurement group_id="O6" value="23600" spread="8577"/>
                    <measurement group_id="O7" value="292.4" spread="80.50"/>
                    <measurement group_id="O8" value="425.9" spread="190.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
        <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part A</description>
        <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
          <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part A</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Percentage of Dose Excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3695" spread="0.2232"/>
                    <measurement group_id="O2" value="0.3927" spread="0.07675"/>
                    <measurement group_id="O3" value="0.4598" spread="0.2008"/>
                    <measurement group_id="O4" value="0.8870" spread="0.3017"/>
                    <measurement group_id="O5" value="1.013" spread="0.2865"/>
                    <measurement group_id="O6" value="0.8781" spread="0.3191"/>
                    <measurement group_id="O7" value="0.1306" spread="0.03594"/>
                    <measurement group_id="O8" value="0.06339" spread="0.02831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
        <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part A</description>
        <time_frame>Part A pre-dose and pooled intervals up to 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O8">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Single Administration of AZD5718 Amorphous and Crystalline Suspension (Part A)</title>
          <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part A</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7241" spread="0.2640"/>
                    <measurement group_id="O2" value="0.6221" spread="0.09344"/>
                    <measurement group_id="O3" value="0.6782" spread="1.599"/>
                    <measurement group_id="O4" value="0.6860" spread="0.1634"/>
                    <measurement group_id="O5" value="0.7093" spread="0.1118"/>
                    <measurement group_id="O6" value="0.6206" spread="0.07438"/>
                    <measurement group_id="O7" value="0.4502" spread="0.1043"/>
                    <measurement group_id="O8" value="0.4312" spread="0.07115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
        <description>To assess the urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
        <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
          <description>To assess the urine PK parameter (CumAe0-24) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>nmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="953.0" spread="253.2"/>
                    <measurement group_id="O2" value="2219" spread="612.0"/>
                    <measurement group_id="O3" value="13720" spread="612.0"/>
                    <measurement group_id="O4" value="18920" spread="6717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
        <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
        <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
          <description>To assess urine PK parameter (Cumfe0-24) estimated by dividing Ae(0-last) by dose after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Percentage of Dose Excreted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7092" spread="0.1884"/>
                    <measurement group_id="O2" value="0.5504" spread="0.1518"/>
                    <measurement group_id="O3" value="1.702" spread="0.2911"/>
                    <measurement group_id="O4" value="1.408" spread="0.4999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
        <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
        <time_frame>Part B only, Day 9 at pooled 3 hour intervals until 24 hours post-dose</time_frame>
        <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of AZD5718 by Assessment of Renal Clearance (CLR) Following a Multiple Daily Doses Administration of AZD5718 Amorphous Suspension (Part B Day 9)</title>
          <description>To assess the urine PK parameter (CLR) after a single administration of AZD5718 Amorphous suspension in Part B Day 9</description>
          <population>All subjects in the safety analysis set for whom at least one dose of AZD5718 and who had evaluable PK data, with no major protocol deviations thought to impact on the analysis of the PK data.</population>
          <units>Liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6490" spread="0.1029"/>
                    <measurement group_id="O2" value="0.7172" spread="0.07593"/>
                    <measurement group_id="O3" value="0.9831" spread="0.04645"/>
                    <measurement group_id="O4" value="0.7368" spread="0.1654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Analysis by ex Vivo Stimulation of Leukotriene B4 (LTB4) Production Using Calcium Ionophore for Part A -Amorphous and Crystalline Suspension</title>
        <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
        <time_frame>Admission to 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose (Part A only)</time_frame>
        <population>All subjects who received at least 1 dose of AZD5718 or placebo and who had at least 1 pre-dose and one post-dose measurement of stimulated LTB4 and who had no major protocol deviations thought to impact on the analysis of the PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>25 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
          </group>
          <group group_id="O2">
            <title>50 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
          </group>
          <group group_id="O3">
            <title>100 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
          </group>
          <group group_id="O4">
            <title>300 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
          </group>
          <group group_id="O5">
            <title>600 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
          </group>
          <group group_id="O6">
            <title>1200 mg - Part A (Amorphous Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
          </group>
          <group group_id="O7">
            <title>Placebo - Part A (Amorphous Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part A (Amorphous suspension)</description>
          </group>
          <group group_id="O8">
            <title>100 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
          </group>
          <group group_id="O9">
            <title>300 mg - Part A (Crystalline Suspension)</title>
            <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
          </group>
          <group group_id="O10">
            <title>Placebo - Part A (Crystalline Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part A (Crystalline suspension)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Analysis by ex Vivo Stimulation of Leukotriene B4 (LTB4) Production Using Calcium Ionophore for Part A -Amorphous and Crystalline Suspension</title>
          <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following a single administration of AZD5718 Amorphous and Crystalline suspension (Part A only)</description>
          <population>All subjects who received at least 1 dose of AZD5718 or placebo and who had at least 1 pre-dose and one post-dose measurement of stimulated LTB4 and who had no major protocol deviations thought to impact on the analysis of the PD data.</population>
          <units>Nanogram/liter (ng/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.689" upper_limit="1.18"/>
                    <measurement group_id="O2" value="0.877" lower_limit="0.741" upper_limit="1.13"/>
                    <measurement group_id="O3" value="0.560" lower_limit="0.200" upper_limit="0.813"/>
                    <measurement group_id="O4" value="0.000219" lower_limit="0" upper_limit="0.00156"/>
                    <measurement group_id="O5" value="0.0000318" lower_limit="0" upper_limit="0.000208"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.0127"/>
                    <measurement group_id="O7" value="0.877" lower_limit="0.496" upper_limit="2.60"/>
                    <measurement group_id="O8" value="0.781" lower_limit="0.484" upper_limit="1.04"/>
                    <measurement group_id="O9" value="0.852" lower_limit="0.532" upper_limit="1.23"/>
                    <measurement group_id="O10" value="0.934" lower_limit="0.813" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" lower_limit="0.787" upper_limit="1.19"/>
                    <measurement group_id="O2" value="0.553" lower_limit="0.120" upper_limit="0.955"/>
                    <measurement group_id="O3" value="0.0213" lower_limit="0.000343" upper_limit="0.332"/>
                    <measurement group_id="O4" value="0.0000451" lower_limit="0" upper_limit="2.80"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0.930" lower_limit="0.414" upper_limit="2.52"/>
                    <measurement group_id="O8" value="0.497" lower_limit="0.201" upper_limit="0.833"/>
                    <measurement group_id="O9" value="0.646" lower_limit="0.363" upper_limit="1.02"/>
                    <measurement group_id="O10" value="0.833" lower_limit="0.413" upper_limit="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.858" lower_limit="0.150" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.124" lower_limit="0.0144" upper_limit="0.543"/>
                    <measurement group_id="O3" value="0.000715" lower_limit="0" upper_limit="0.0358"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000155"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0.000197"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.0000955"/>
                    <measurement group_id="O7" value="0.943" lower_limit="0.671" upper_limit="2.74"/>
                    <measurement group_id="O8" value="0.245" lower_limit="0.0193" upper_limit="0.591"/>
                    <measurement group_id="O9" value="0.292" lower_limit="0.0161" upper_limit="1.34"/>
                    <measurement group_id="O10" value="0.841" lower_limit="0.372" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.672" lower_limit="0.0415" upper_limit="1.34"/>
                    <measurement group_id="O2" value="0.0271" lower_limit="0.00348" upper_limit="0.421"/>
                    <measurement group_id="O3" value="0.000165" lower_limit="0" upper_limit="0.00218"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000217"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0.965" lower_limit="0.674" upper_limit="2.96"/>
                    <measurement group_id="O8" value="0.0449" lower_limit="0.00161" upper_limit="0.134"/>
                    <measurement group_id="O9" value="0.0532" lower_limit="0.000882" upper_limit="0.799"/>
                    <measurement group_id="O10" value="0.647" lower_limit="0.449" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.616" lower_limit="0.0234" upper_limit="0.925"/>
                    <measurement group_id="O2" value="0.0177" lower_limit="0.00125" upper_limit="0.0904"/>
                    <measurement group_id="O3" value="0.000304" lower_limit="0" upper_limit="0.00338"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0.952" lower_limit="0.772" upper_limit="2.01"/>
                    <measurement group_id="O8" value="0.0187" lower_limit="0.000422" upper_limit="0.0594"/>
                    <measurement group_id="O9" value="0.0329" lower_limit="0" upper_limit="0.394"/>
                    <measurement group_id="O10" value="0.635" lower_limit="0.0922" upper_limit="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.443" lower_limit="0.0274" upper_limit="1.17"/>
                    <measurement group_id="O2" value="0.00669" lower_limit="0.00296" upper_limit="0.0307"/>
                    <measurement group_id="O3" value="0.000249" lower_limit="0" upper_limit="0.000884"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000607"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0.000330"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.000267"/>
                    <measurement group_id="O7" value="1.20" lower_limit="0.883" upper_limit="4.01"/>
                    <measurement group_id="O8" value="0.0267" lower_limit="0.00503" upper_limit="0.0888"/>
                    <measurement group_id="O9" value="0.00819" lower_limit="0.000518" upper_limit="0.147"/>
                    <measurement group_id="O10" value="0.842" lower_limit="0.337" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.415" lower_limit="0.0357" upper_limit="1.08"/>
                    <measurement group_id="O2" value="0.0234" lower_limit="0.00890" upper_limit="0.104"/>
                    <measurement group_id="O3" value="0.000518" lower_limit="0" upper_limit="0.0114"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000708"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0.000646"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.000148"/>
                    <measurement group_id="O7" value="1.41" lower_limit="1.00" upper_limit="3.63"/>
                    <measurement group_id="O8" value="0.0634" lower_limit="0.00861" upper_limit="0.162"/>
                    <measurement group_id="O9" value="0.00880" lower_limit="0.000418" upper_limit="0.212"/>
                    <measurement group_id="O10" value="1.39" lower_limit="0.873" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" lower_limit="0.0612" upper_limit="1.40"/>
                    <measurement group_id="O2" value="0.334" lower_limit="0.0635" upper_limit="0.621"/>
                    <measurement group_id="O3" value="0.0515" lower_limit="0.000546" upper_limit="0.210"/>
                    <measurement group_id="O4" value="0.00116" lower_limit="0" upper_limit="0.00213"/>
                    <measurement group_id="O5" value="0.000106" lower_limit="0" upper_limit="0.000469"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.000149"/>
                    <measurement group_id="O7" value="1.36" lower_limit="0.843" upper_limit="3.79"/>
                    <measurement group_id="O8" value="0.247" lower_limit="0.0854" upper_limit="0.381"/>
                    <measurement group_id="O9" value="0.188" lower_limit="0.00673" upper_limit="0.794"/>
                    <measurement group_id="O10" value="1.50" lower_limit="0.226" upper_limit="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.874" lower_limit="0.581" upper_limit="1.55"/>
                    <measurement group_id="O2" value="0.470" lower_limit="0.394" upper_limit="0.716"/>
                    <measurement group_id="O3" value="0.435" lower_limit="0.111" upper_limit="0.702"/>
                    <measurement group_id="O4" value="0.0698" lower_limit="0.00817" upper_limit="0.197"/>
                    <measurement group_id="O5" value="0.00100" lower_limit="0.000480" upper_limit="0.0135"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0.000308"/>
                    <measurement group_id="O7" value="1.04" lower_limit="0.611" upper_limit="3.12"/>
                    <measurement group_id="O8" value="0.472" lower_limit="0.249" upper_limit="0.747"/>
                    <measurement group_id="O9" value="0.369" lower_limit="0.220" upper_limit="0.463"/>
                    <measurement group_id="O10" value="0.986" lower_limit="0.910" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="0.676" upper_limit="3.35"/>
                    <measurement group_id="O2" value="1.22" lower_limit="0.620" upper_limit="2.15"/>
                    <measurement group_id="O3" value="0.813" lower_limit="0.592" upper_limit="1.29"/>
                    <measurement group_id="O4" value="0.379" lower_limit="0.205" upper_limit="1.23"/>
                    <measurement group_id="O5" value="0.0142" lower_limit="0.00581" upper_limit="0.0405"/>
                    <measurement group_id="O6" value="0.00108" lower_limit="0.000120" upper_limit="0.0643"/>
                    <measurement group_id="O7" value="1.70" lower_limit="1.12" upper_limit="4.28"/>
                    <measurement group_id="O8" value="1.04" lower_limit="0.831" upper_limit="1.47"/>
                    <measurement group_id="O9" value="1.04" lower_limit="0.564" upper_limit="1.49"/>
                    <measurement group_id="O10" value="1.31" lower_limit="1.08" upper_limit="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48.0 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="0.947" upper_limit="2.31"/>
                    <measurement group_id="O2" value="1.05" lower_limit="0.808" upper_limit="1.74"/>
                    <measurement group_id="O3" value="0.739" lower_limit="0.531" upper_limit="0.884"/>
                    <measurement group_id="O4" value="0.560" lower_limit="0.411" upper_limit="1.40"/>
                    <measurement group_id="O5" value="0.290" lower_limit="0.0790" upper_limit="0.484"/>
                    <measurement group_id="O6" value="0.0632" lower_limit="0.000720" upper_limit="0.211"/>
                    <measurement group_id="O7" value="1.23" lower_limit="0.689" upper_limit="5.46"/>
                    <measurement group_id="O8" value="0.638" lower_limit="0.482" upper_limit="0.918"/>
                    <measurement group_id="O9" value="0.940" lower_limit="0.512" upper_limit="1.29"/>
                    <measurement group_id="O10" value="0.893" lower_limit="0.687" upper_limit="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamic Analysis by ex Vivo Stimulation of LTB4 Production Using Calcium Ionophore for Part B - Amorphous Suspension</title>
        <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following multiple administration of AZD5718 Amorphous suspension (Part B only)</description>
        <time_frame>Admission, predose and 0.5, 1, 2, 3, 4, 6, 8, 24, 36 and 48 hours post-dose</time_frame>
        <population>All subjects who received at least 1 dose of AZD5718 or placebo and who had at least 1 pre-dose and one post-dose measurement of stimulated LTB4 and who had no major protocol deviations thought to impact on the analysis of the PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>60 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O2">
            <title>180 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O3">
            <title>360 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O4">
            <title>600 mg - Part B (Amorphous Suspension)</title>
            <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
          </group>
          <group group_id="O5">
            <title>Placebo - Part B (Amorphous Suspension)</title>
            <description>2 participants per dose level received single dose of placebo in Part B (Amorphous suspension)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Analysis by ex Vivo Stimulation of LTB4 Production Using Calcium Ionophore for Part B - Amorphous Suspension</title>
          <description>To assess the change from baseline in the ex vivo stimulated LTB4 production using calcium ionophore in venous blood samples following multiple administration of AZD5718 Amorphous suspension (Part B only)</description>
          <population>All subjects who received at least 1 dose of AZD5718 or placebo and who had at least 1 pre-dose and one post-dose measurement of stimulated LTB4 and who had no major protocol deviations thought to impact on the analysis of the PD data.</population>
          <units>Nanogram/liter (ng/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" lower_limit="0.00815" upper_limit="0.915"/>
                    <measurement group_id="O2" value="0.00171" lower_limit="0.000244" upper_limit="0.0284"/>
                    <measurement group_id="O3" value="0.0000984" lower_limit="0" upper_limit="0.000903"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000128"/>
                    <measurement group_id="O5" value="1.49" lower_limit="1.11" upper_limit="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654" lower_limit="0.305" upper_limit="1.49"/>
                    <measurement group_id="O2" value="0.434" lower_limit="0.121" upper_limit="0.816"/>
                    <measurement group_id="O3" value="0.00350" lower_limit="0.00162" upper_limit="0.0440"/>
                    <measurement group_id="O4" value="0.000771" lower_limit="0" upper_limit="0.00902"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.510" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" lower_limit="0.147" upper_limit="1.24"/>
                    <measurement group_id="O2" value="0.203" lower_limit="0.0116" upper_limit="0.561"/>
                    <measurement group_id="O3" value="0.00609" lower_limit="0.00131" upper_limit="0.0969"/>
                    <measurement group_id="O4" value="0.000893" lower_limit="0" upper_limit="0.00343"/>
                    <measurement group_id="O5" value="1.10" lower_limit="0.743" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.731" lower_limit="0.230" upper_limit="1.54"/>
                    <measurement group_id="O2" value="0.294" lower_limit="0.00887" upper_limit="1.61"/>
                    <measurement group_id="O3" value="0.00328" lower_limit="0.000204" upper_limit="0.0229"/>
                    <measurement group_id="O4" value="0.000152" lower_limit="0" upper_limit="0.00191"/>
                    <measurement group_id="O5" value="0.950" lower_limit="0.787" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.421" lower_limit="0.350" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.159" lower_limit="0.000491" upper_limit="0.842"/>
                    <measurement group_id="O3" value="0.00467" lower_limit="0.0000985" upper_limit="0.0498"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.00110"/>
                    <measurement group_id="O5" value="0.893" lower_limit="0.591" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.472" lower_limit="0.148" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.227" lower_limit="0.0148" upper_limit="2.18"/>
                    <measurement group_id="O3" value="0.00242" lower_limit="0.000461" upper_limit="0.0226"/>
                    <measurement group_id="O4" value="0.000158" lower_limit="0" upper_limit="0.00126"/>
                    <measurement group_id="O5" value="0.895" lower_limit="0.488" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.511" lower_limit="0.134" upper_limit="0.907"/>
                    <measurement group_id="O2" value="0.376" lower_limit="0.00763" upper_limit="2.04"/>
                    <measurement group_id="O3" value="0.00210" lower_limit="0.000188" upper_limit="0.0527"/>
                    <measurement group_id="O4" value="0.000195" lower_limit="0" upper_limit="0.00420"/>
                    <measurement group_id="O5" value="1.05" lower_limit="0.791" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.583" lower_limit="0.170" upper_limit="0.962"/>
                    <measurement group_id="O2" value="0.134" lower_limit="0.00223" upper_limit="0.782"/>
                    <measurement group_id="O3" value="0.00187" lower_limit="0.000169" upper_limit="0.0255"/>
                    <measurement group_id="O4" value="0.000342" lower_limit="0" upper_limit="0.00156"/>
                    <measurement group_id="O5" value="0.904" lower_limit="0.625" upper_limit="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.288" lower_limit="0.114" upper_limit="0.408"/>
                    <measurement group_id="O2" value="0.0360" lower_limit="0.00731" upper_limit="0.274"/>
                    <measurement group_id="O3" value="0.00171" lower_limit="0" upper_limit="0.00622"/>
                    <measurement group_id="O4" value="0.000130" lower_limit="0" upper_limit="0.000597"/>
                    <measurement group_id="O5" value="0.661" lower_limit="0.518" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" lower_limit="0.0557" upper_limit="0.432"/>
                    <measurement group_id="O2" value="0.0266" lower_limit="0.00483" upper_limit="0.153"/>
                    <measurement group_id="O3" value="0.000908" lower_limit="0" upper_limit="0.00357"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000368"/>
                    <measurement group_id="O5" value="0.982" lower_limit="0.292" upper_limit="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.00153"/>
                    <measurement group_id="O2" value="0.000198" lower_limit="0" upper_limit="0.00109"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.000371"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000123"/>
                    <measurement group_id="O5" value="0.812" lower_limit="0.270" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000109" lower_limit="0" upper_limit="0.000387"/>
                    <measurement group_id="O2" value="0.0000944" lower_limit="0" upper_limit="0.000606"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.000359"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0.921" lower_limit="0.407" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10, 12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0143" lower_limit="0.00140" upper_limit="0.0357"/>
                    <measurement group_id="O2" value="0.00247" lower_limit="0" upper_limit="0.00772"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0.000390"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.00109"/>
                    <measurement group_id="O5" value="1.20" lower_limit="0.289" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11, 24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" lower_limit="0.105" upper_limit="0.355"/>
                    <measurement group_id="O2" value="0.0901" lower_limit="0.00314" upper_limit="0.321"/>
                    <measurement group_id="O3" value="0.000426" lower_limit="0" upper_limit="0.00130"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0.000279"/>
                    <measurement group_id="O5" value="1.20" lower_limit="0.665" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12, 48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.550" lower_limit="0.193" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.906" lower_limit="0.320" upper_limit="1.84"/>
                    <measurement group_id="O3" value="0.304" lower_limit="0.0743" upper_limit="0.856"/>
                    <measurement group_id="O4" value="0.0583" lower_limit="0.00295" upper_limit="0.813"/>
                    <measurement group_id="O5" value="1.05" lower_limit="0.433" upper_limit="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to last follow-up visit (7-10 days after last dose), up to 6 weeks (Part A) and up to 8 weeks (Part B)</time_frame>
      <desc>All randomized subjects who received at least 1 dose of IMP and for whom any safety post dose-data were available were included in the safety analysis for the study. A treatment-emergent adverse event (TEAE) was defined as an AE with onset (start date/time) after the first dose of IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>25 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 25 mg in amorphous state</description>
        </group>
        <group group_id="E2">
          <title>50 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 50 mg in amorphous state</description>
        </group>
        <group group_id="E3">
          <title>100 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 100 mg in amorphous state</description>
        </group>
        <group group_id="E4">
          <title>300 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 300 mg in amorphous state</description>
        </group>
        <group group_id="E5">
          <title>600 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 600 mg in amorphous state</description>
        </group>
        <group group_id="E6">
          <title>1200 mg - Part A (Amorphous Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 1200 mg in amorphous state</description>
        </group>
        <group group_id="E7">
          <title>Placebo - Part A (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Amorphous suspension)</description>
        </group>
        <group group_id="E8">
          <title>100 mg - Part A (Crystalline Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 100 mg in crystalline state</description>
        </group>
        <group group_id="E9">
          <title>300 mg - Part A (Crystalline Suspension)</title>
          <description>Participants received single dose of oral suspension of AZD5718 300 mg in crystalline state.
Presented only based on 5 subjects data.</description>
        </group>
        <group group_id="E10">
          <title>Placebo - Part A (Crystalline Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part A (Crystalline suspension)</description>
        </group>
        <group group_id="E11">
          <title>60 mg - Part B (Amorphous Suspension)</title>
          <description>Participants received multiple doses of oral suspension of AZD5718 60 mg in amorphous state in 6 cohorts</description>
        </group>
        <group group_id="E12">
          <title>180 mg - Part B (Amorphous Suspension)</title>
          <description>Participants received multiple doses of oral suspension of AZD5718 180 mg in amorphous state in 6 cohorts</description>
        </group>
        <group group_id="E13">
          <title>360 mg - Part B (Amorphous Suspension)</title>
          <description>Participants received multiple doses of oral suspension of AZD5718 360 mg in amorphous state in 6 cohorts</description>
        </group>
        <group group_id="E14">
          <title>600 mg - Part B (Amorphous Suspension)</title>
          <description>Participants received multiple doses of oral suspension of AZD5718 600 mg in amorphous state in 6 cohorts</description>
        </group>
        <group group_id="E15">
          <title>Placebo - Part B (Amorphous Suspension)</title>
          <description>2 participants per dose level received single dose of placebo in Part B (Amorphous suspension)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>A study to assess the safety, tolerability, pharmacokinetics &amp; dynamics of AZD5718 in healthy male</name_or_title>
      <organization>AstraZeneca AB</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

